| 摘要 |
PROBLEM TO BE SOLVED: To provide a specific form of anhydrous crystalline orvepitant maleate as an NK1 antagonist, pharmaceutical formulations comprising the same, its use in therapy and processes for preparing the same.SOLUTION: The invention provides anhydrous crystalline orvepitant maleate (Form 1) having substantially the same X-ray powder diffraction (XRD) pattern as in figure 1 of a specific X-ray powder diffraction, where the XRD pattern is expressed in terms of 2&thetas; angles and obtained with a diffractometer using copper Kα X-radiation. The invention also provides use thereof. |
